Written by: Rafael Guimarães, MS & Kristen DiFilippo, PhD, RDN
Glucagon-like peptide 1 receptor agonists, commonly known as GLP-1 medications, are increasingly used in the treatment of type 2 diabetes and obesity (Drucker 2018; Nauck et al. 2021). These medications improve glycemic control and promote weight loss by slowing gastric emptying, enhancing insulin secretion, and reducing appetite. While their clinical benefits are well established, their growing use raises important considerations for dietary intake, nutritional status, and long-term health outcomes.
How GLP-1 Medications Influence Dietary Intake
GLP-1 medications reduce hunger and increase satiety, leading to decreased total energy intake (Nauck et al., 2021; Shah and Vella, 2014). Clinical trials consistently show meaningful reductions in caloric intake and body weight among individuals using these therapies (Davies et al., 2021; Wilding et al., 2021). However, a lower quantity of food intake does not necessarily translate into improved diet quality.
Reduced appetite may also lead to irregular eating patterns or meal skipping (Shah and Vella, 2014). In practice, individuals may eat less frequently or consume smaller portions without prioritizing nutrient-dense foods. This pattern can result in diets that are lower in essential vitamins and minerals despite reduced caloric intake.
Risk of Micronutrient Inadequacy
Weight loss, particularly when rapid or substantial, is associated with an increased risk of micronutrient deficiencies (Astrup and Rössner, 2000; Jensen et al., 2013). This risk may be amplified in individuals using GLP-1 medications due to sustained reductions in food intake over time.
Micronutrients such as magnesium, vitamin B12, iron, and calcium may be particularly affected, especially in individuals with pre-existing dietary limitations. Evidence from weight loss interventions shows that reduced energy intake is often accompanied by lower micronutrient intake unless diet quality is carefully managed (Ledikwe et al., 2006). For individuals with diabetes, who may already have altered nutrient metabolism, this can have important clinical implications.
Changes in Body Composition
Although GLP-1 medications are effective for weight loss, reductions in body weight may include both fat mass and lean mass. Some studies indicate that a portion of weight loss associated with GLP-1 therapy includes loss of fat-free mass (Wilding et al., 2021)
Preserving lean mass is essential, especially in individuals with diabetes, due to its role in glucose metabolism (Wolfe, 2006; Wilding et al., 2021). Loss of muscle mass can negatively affect metabolic health and functional capacity. Adequate protein intake and resistance training are important strategies to minimize this loss (Lahav et al., 2025; Morton et al., 2018).
Gastrointestinal Effects and Eating Behavior
GLP-1 medications commonly cause gastrointestinal side effects such as nausea, vomiting, and early satiety (Nauck et al., 2021). These symptoms can further reduce food intake and influence eating behavior.
Patients may avoid certain foods or significantly reduce portion sizes, which can impact both macronutrient and micronutrient intake. In many cases, these side effects improve over time, but nutritional monitoring is especially important during the early phases of medication use (Nauck et al., 2021).
Implications for Nutrition Care
The increasing use of GLP-1 medications highlights the importance of integrating nutrition care into diabetes management. Although these medications are effective for glycemic control and weight loss, they do not replace the need for structured dietary guidance (Evert et al., 2013; Davies et al., 2021).
The Academy of Nutrition and Dietetics emphasizes that individuals using anti-obesity or diabetes medications require ongoing nutrition assessment and counseling to ensure adequate nutrient intake, support healthy eating behaviors, and prevent potential nutrient deficiencies associated with reduced energy intake (Academy of Nutrition and Dietetics, 2025).
Dietitians play a critical role in helping individuals maintain adequate nutrient intake despite reduced appetite. This includes supporting nutrient-dense food choices, establishing regular eating patterns, and monitoring for potential deficiencies (Evert et al., 2013). Nutrition care should also consider individual factors such as baseline diet quality, socioeconomic context, and access to healthy foods.
Conclusion
GLP-1 medications represent a major advancement in the treatment of type 2 diabetes and obesity. However, their effects on appetite and energy intake have important nutritional implications. Reduced food intake may increase the risk of micronutrient inadequacy, changes in body composition, and altered eating behaviors.
Integrating nutrition care with pharmacological treatment is essential to ensure that improvements in glycemic control and weight are not achieved at the expense of nutritional status. A comprehensive approach that combines medication, dietary guidance, and ongoing monitoring can support better long-term outcomes for individuals living with diabetes.
References
Academy of Nutrition and Dietetics. 2025. “Obesity Medications.” 2025. https://www.eatrightpro.org/obesity-medication.
Astrup, A., and S. Rössner. 2000. “Lessons from Obesity Management Programmes: Greater Initial Weight Loss Improves Long-Term Maintenance.” Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 1 (1): 17–19.
Davies, Melanie, Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., et al. 2021. “Semaglutide 2·4 Mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial.” Lancet 397 (10278): 971–84.
Drucker, D. J. 2018. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism 27 (4): 740–56.
Evert, A. B., Boucher, J. L., Cypress, M., Dunbar, S. A., Franz, M. J., Mayer-Davis, E. J., Neumiller, J. J., et al. 2013. “Nutrition Therapy Recommendations for the Management of Adults with Diabetes.” Diabetes Care 36 (11): 3821–42.
Jensen, Michael D., Ryan, D. H., Apovian, C. M., Ard, J.D., Comuzzie, A. G., Donato, K. A., Hu, F. B., et al. 2013. “Reprint: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” Journal of the American Pharmacists Association: JAPhA 129 (25 Suppl 2): e3.
Lahav, Yair, Yavetz, R., and Gepner, Y. 2025. “Resistance Training as a Key Strategy for High-Quality Weight Loss in Men and Women.” Frontiers in Endocrinology 16: 1725500.
Ledikwe, Jenny H., Blanck, H. M., Khan, L. K., Serdula, M. K., Seymour, J. D., Tohill, B. C., and Rolls, B. J. 2006. “Low-Energy-Density Diets Are Associated with High Diet Quality in Adults in the United States.” Journal of the American Dietetic Association 106 (8): 1172–80.
Morton, Robert W., Murphy, K. T., McKellar, S. R., Schoenfeld, B. J., Henselmans, M., Helms, E., Aragon, A. A., et al. 2018. “A Systematic Review, Meta-Analysis and Meta-Regression of the Effect of Protein Supplementation on Resistance Training-Induced Gains in Muscle Mass and Strength in Healthy Adults.” British Journal of Sports Medicine 52 (6): 376–84.
Nauck, Michael A., Quast, D. R., Wefers, J., and Meier, J. J. 2021. “GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – State-of-the-Art.” Molecular Metabolism 46 (101102): 101102.
Shah, Meera, and Vella, A. 2014. “Effects of GLP-1 on Appetite and Weight.” Reviews in Endocrine & Metabolic Disorders 15 (3): 181–87.
Wilding, John P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., et al. 2021. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicine 384 (11): 989–1002.
Wilding, John P. H., Batterham, R. L., and Salvatore Calanna Phd Luc F. Van Gaal MDPhD Barbara M McGowan MD PhD Julio Rosenstock MD Marie T D Tran MD PhD Sean Wharton MD PharmD Koutaro Yokote MD PhD Niels Zeuthen MSc Robert F Kushner. 2021. “Impact of Semaglutide on Body Composition in Adults with Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.” Journal of the Endocrine Society 5 (Supplement_1): A16–17.
Wolfe, R. R. 2006. “The Underappreciated Role of Muscle in Health and Disease.” The American Journal of Clinical Nutrition 84 (3): 475–82.
Photo credit: Haberdoedas, via Unsplash
